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plete cytogenetic and molecular. Prognosis was assigned to each category,
according to disease progression and mortality. Prognosis was also assigned to
BMT patients. Unit costs were drawn from national databases, and multiplied by
resource use (driven by response level and disease status) to estimate total costs.
Health benefits weremeasured using quality-adjusted life years (QALYs), based on
the patient’s current health status and level of response. Univariate and probabi-
listic sensitivity analyses were conducted to estimate the confidence around the
results. RESULTS: Dasatinib resulted in 6.425 QALYs, at a total cost of £314,413, per
patient. QALYs and costs for comparators were as follows: imatinib 400mg, 1.485,
£135,326; imatinib 600mg, 2.394, £173,705; imatininb 800mg, 5.910, £350,365; nilo-
tinib, 6.235, £228,576; interferon-a, 1.664, £6,764; BMT, 4.738, £302, 937. Incremental
cost-effectiveness ratios (ICER) for dasatinib against competitors were as follows:
imatinib 400mg, £36,251; imatinib 600mg, £34,907; imatinib 800mg, dominant; ni-
lotinib, dominant; interferon-a, £38,877; BMT, dominant. CONCLUSIONS:Dasatinib
was more effective than imatinib 400mg, 600mg 800mg, nilotinib, interferon-a and
BMT in the treatment of chronic-phase imatinib-resistant patients CML. The analysis
estimates dasatinib treatment to be less costly than imatinib 800mg, nilotinib and
BMT, dominating these treatments in the cost-effectiveness analysis. Dasatinib is
therefore a cost-effective treatment option for patients in the CP of CML.
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OBJECTIVES: Chronic myelogenous leukaemia (CML) is a progressive disease asso-
ciated with significant health and economic burden. This study estimates the life-
time costs and health outcomes associated with dasatinib in the treatment of
imatinib-resistant CML patients who have the accelerated or blast stages of the
disease.METHODS: AMarkovmodel was developed to estimate lifetime outcomes
based on initial best response, which was defined as: no response, complete
haematologic, partial cytogenetic, complete cytogenetic, molecular. Prognosis was
assigned to each category, according to disease progression and mortality. Unit
costs were drawn from national databases, and multiplied by resource use (driven
by response level and disease status) to estimate total costs. Health benefits were
measured using quality-adjusted life years (QALYs), based on patients’ health sta-
tus and response. Univariate and probabilistic sensitivity analyses were conducted
to estimate confidence around the results. RESULTS: In AP, dasatinib resulted in
2.603 QALYs, at a cost of £170,478 per patient. QALYs and costs for comparators
were: imatinib 600mg, 0.583, £88,949; imatininb 800mg, 0.583, £96,552; nilotinib,
1.697, £141,128; BMT, 2.861, £230,277. Incremental cost-effectiveness ratios (ICER)
for dasatinib against competitors were: imatinib 600mg, £40,357; imatinib 800mg,
£36,594; nilotinib, £32,405, BMT, £231,650. In BP, dasatinib resulted in 0.485 QALYs,
at a total cost of £105,103, per patient. QALYs and costs for comparators were:
imatinib 600mg, 0.240, £108,306; imatinib 800mg, 0.240, £115,123; BMT, 1.757,
£173,892. ICERs for dasatinib against competitors were: imatinib 600mg, dominant;
imatinib 800mg, dominant; BMT, £54,093. CONCLUSIONS: In imatinib-resistant AP
CML, dasatinib was more effective than imatinib 600mg, 800mg and nilotinib, and
less costly than BMT. In BP CML, dasatinib wasmore effective than imatinib 600mg
and 800mg and less costly than imatinib 600mg, 800mg, nilotinib and BMT. Dasat-
inib is, therefore, cost-effectiveness when compared against other pharmacologi-
cal interventions in the treatment of advanced stages of CML.
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OBJECTIVES: Decision analysis (DA) is commonly used to perform economic eval-
uations of new pharmaceuticals. However, DA analyses can also be used to deter-
mine a drug price that would be considered cost effective based on recommended
thresholds for economic value. Usingmultiples of Malaysia’s per capita GDP as the
threshold for economic value as suggested by the World Health Organization
(WHO), DA was used to estimate a price per dose for bevacizumab in Malaysia, a
drug that provides a 1.4 month survival benefit to patients with metastatic colo-
rectal cancer (mCRC).METHODS: A DA model was developed to simulate progres-
sion free and overall survival in mCRC patients receiving chemotherapy with and
without bevacizumab. Outcomes for cancer control and side effects were obtained
from randomized trials evaluating 1st and 2nd line chemotherapy in mCRC. Costs
for chemotherapy and side effects management were obtained from both public
and private hospitals in Malaysia. Utility estimates measured as quality adjusted
life years (QALYs) were determined by interviewing 24 oncology nurses using the
Time Trade-Off technique. The price per dose was then estimated using a target
threshold of $44,400 per QALY gained, which is three times the Malaysian per
capita GDP. RESULTS: A cost effective price for bevacizumab could not be reached
because of the short survival benefit provided. If the drug were able to improve
survival from 1.4 to 3 or 6 months, then the price per dose could be $U.S.567 and
$U.S.1,258 and be considered cost effective in Malaysia according to the WHO
criteria. CONCLUSIONS: The use of DA modeling for estimating drug price is a
powerful technique to ensure value formoney. Such information can be of value to
both drug manufacturers and formulary committees because it would facilitate
negotiations for value-based pricing in a given jurisdiction.
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OBJECTIVES:One of themajor barriers to cancer drug access has been price, which is
oftenbeyond themeansofnationalhealth carebudgets in lessdevelopedcountries. In
this study,wepresent anovel approach to estimate a value basedprice for newcancer
drugs that considers thewealthof anation.Todemonstrate this approach, pharmaco-
economic (PE) modeling was used to estimate a value based South African price for
bevacizumab, a drug that provides a 1.4 month survival benefit to patients with met-
astatic colorectal cancer (mCRC). The threshold used for economic value was 3 times
the South African per capita gross domestic product (GDP), as recommended by the
WorldHealthOrganization (WHO).METHODS:APEmodelwas developed to simulate
theoutcomes inmCRCpatients receiving chemotherapybevacizumab.Clinical data
were obtained from randomized trials and costs from a South African cancer center.
Utility estimateswere determined by interviewing 16 oncology nurses involved in the
care of mCRC patients. A price per dose of bevacizumab was then estimated using a
target threshold of $U.S.32,000 per quality adjusted life year (QALY) gained, which is 3
times the South African per capita GDP. RESULTS: A cost effective price for bevaci-
zumabcouldnot be reachedbecause of the short survival benefit. If thedrugwere able
to improve survival from 1.4 to 3 or 6 months, then the price per dose could be
$U.S.58.00 and $U.S.258.00 and be considered cost effective in South Africa according
to the WHO criteria. CONCLUSIONS: A value based pricing approach using PE mod-
eling and the WHO criteria for economic value is feasible for South Africa. This ap-
proachwould be a good starting point for opening dialogue betweenmedical schemes
and the pharmaceutical industry to identify an optimal drug price that would be ac-
ceptable to all of the key stakeholders.
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OBJECTIVES:Adjuvant chemotherapy decisions for womenwith early-stage breast
cancer are complex. Oncotype DX, a gene expression profiling test, is validated at
predicting distant recurrence-free response in patients with ER LN- early-stage
breast cancer. This enables chemotherapy to be better targeted at higher risk pa-
tients than is possible through the use of Adjuvant! Online (AOL) or clinical judge-
ment alone. However, existing cost-effectiveness analyses of Oncotype DX have
numerous limitations: in particular, they consider a limited range of strategies and
do not separately consider intermediate risk patients identified through either AOL
or Oncotype DX. Our objective was to build an Ontario-based cost-effectiveness
analysis which comprehensively addresses these limitations.METHODS:We built
upon a Markov model developed by Tsoi and colleagues, using data from the
NSABP B-14 and B-20 clinical trials.We assumed that AOL andOncotypeDXmay be
provided separately or sequentially and considered the chemotherapy decision
separately for every possible risk group, resulting in 1000 unique strategies for the
provision of AOL, Oncotype DX and chemotherapy. RESULTS: Oncotype DX ap-
pears cost-effective for all patients, regardless of a patient’s initial AOL risk assess-
ment. The highest ICER is in patients at low AOL risk ($29,000 per QALY), while
Oncotype DX dominates in patients at high AOL risk. Chemotherapy appears cost-
effective only in patients at intermediate or high Oncotype DX risk. The highest
ICER is in patients at low AOL and intermediate Oncotype DX risk ($64,000 per
QALY). Chemotherapy is dominated in patients at low Oncotype DX risk.
CONCLUSIONS: Oncotype DX appears to be cost-effective for all Ontario women
with ER LN- early-stage breast cancer, regardless of the woman’s initial AOL risk
assessment. These results have informed the Ontario Health Technology Advisory
Committee’s recent deliberations regarding the funding of OncotypeDX inOntario.
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OBJECTIVES: The main objective of this study was to evaluate the utilisation of
antineoplastic drugs during the period of 2004-2009 in Slovak Republic.METHODS:
Data involving the number of medicine packages, DDD and financial expenditures
abstracted from the Slovak Institute for Drug control were analysed to evaluate the
antineoplastic agents consumption. RESULTS: The obtained data showed slight
increase in antineoplastic agents consumption from 2004 (21,03 DID (DDD/1000
inhabitants/ day) to 2007 (30,94 DID). Between 2007 and 2009 slight decrase in DID
(from 30,94 in 2007 to 27,10 in 2009) was observed. Antimetabolits raised DID con-
sumption between 2004 (9,88) and 2007 (14,13) and declined in 2009 (10,12 ). The
consumption of alkylating agents in terms ofDIDwas varying from4,4 in 2004 to 8,3
in 2007 and 7,38 in 2009, cytotoxic antibiotics and related substances reached 0,41
in 2004, 0,74 in 2007 and 0,73 in 2009, plant alkaloids and other natural products
quoted 2,04 in 2004 and 2,67 in 2009. Total expenditures for antineoplastic drugs
multiplied from 21 736 185 € (2004) to 105 589 161 € (2009). Highest consumption in
terms of financial units was reached in 2004 by: docetaxel (2 328 233€ ), paclitaxel
( 2 259 313€ ) and gemcitabine (2 062 914€ ); in 2009 by: bevacizumab (17 049 381 €),
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